Cowen & Co. analyst Boris Peaker maintained a Buy rating on Endocyte (NASDAQ: ECYT) today. The company’s shares opened today at $14.44, close to its 52-week high of $15.45.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.6% and a 52.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Endocyte has an analyst consensus of Moderate Buy, with a price target consensus of $17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.45 and a one-year low of $1.17. Currently, Endocyte has an average volume of 1.36M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
